Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Ingrid Herr

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2389-6300; OpenAlex author ID A5091265792. Sources: ClinicalTrials.gov.

Their work

Papers
50 (first author 1, last author 39)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
82
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper, 1 trial · 2014: 6 papers · 2015: 1 paper · 2016: 4 papers · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: 4 papers · 2021: 4 papers · 2022: 6 papers · 2023: 4 papers · 2024: 4 papers · 2025: 5 papers · 2026: 2 papers

Papers 50

  1. Arp2/3 complex and β1 integrin drive an invasive front through extracellular matrix adaptation in pancreatic cancer. Co-author DOI 10.1002/ijc.70376↗
  2. Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41388-026-04026-x↗
  3. ARP2/3 complex affects myofibroblast differentiation and migration in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35246↗
  4. Baicalein disrupts TGF-β-induced EMT in pancreatic cancer by FTO-dependent m6A demethylation of ZEB1. Co-author DOI 10.1016/j.bbamcr.2025.119969↗
  5. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  6. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  7. Retraction: Up-regulation of microRNA let-7c by quercetin inhibits pancreatic cancer progression by activation of Numbl. Last author DOI 10.18632/oncotarget.28751↗
  8. Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Last author DOI 10.1038/s41419-023-06385-9↗
  9. Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Last author DOI 10.18632/oncotarget.28527↗
  10. Corrigendum: Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer. Last author DOI 10.3389/fonc.2024.1343421↗
  11. Multi-Algorithm Analysis Reveals Pyroptosis-Linked Genes as Pancreatic Cancer Biomarkers. Last author DOI 10.3390/cancers16020372↗
  12. Corrigendum to: "Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death" [Biomed. Pharmacother. 153 (2… Last author DOI 10.1016/j.biopha.2023.115879↗
  13. Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer. Last author DOI 10.1186/s12943-023-01834-7↗
  14. [Corrigendum] Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-β-driven progression of pancreatic cancer. Last author DOI 10.3892/ijo.2023.5543↗
  15. [Corrigendum] Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer. Last author DOI 10.3892/or.2023.8626↗
  16. Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death. Last author DOI 10.1016/j.biopha.2022.113511↗
  17. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.matbio.2022.11.002↗
  18. Glucocorticoid-induced microRNA-378 signaling mediates the progression of pancreatic cancer by enhancing autophagy. Last author DOI 10.1038/s41419-022-05503-3↗
  19. Machine-Learning-Based Bibliometric Analysis of Pancreatic Cancer Research Over the Past 25 Years. First author DOI 10.3389/fonc.2022.832385↗
  20. UHMK1 Is a Novel Marker for Personalized Prediction of Pancreatic Cancer Prognosis. Last author DOI 10.3389/fonc.2022.834647↗
  21. Corrigendum: Establishment of Tumor Treating Fields Combined With Mild Hyperthermia as Novel Supporting Therapy for Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.889215↗
  22. Therapy of pancreatic cancer with alternating electric fields: Limitations of the method. Co-author DOI 10.1016/j.bioelechem.2021.107881↗
  23. Establishment of Tumor Treating Fields Combined With Mild Hyperthermia as Novel Supporting Therapy for Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.738801↗
  24. Sulforaphane Inhibits the Expression of Long Noncoding RNA H19 and Its Target APOBEC3G and Thereby Pancreatic Cancer Progression. Last author DOI 10.3390/cancers13040827↗
  25. Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer. Last author DOI 10.3390/cancers13194770↗
  26. Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study. Last author DOI 10.1007/s10637-019-00826-z↗
  27. Inhibition of miR30a-3p by sulforaphane enhances gap junction intercellular communication in pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.10.042↗
  28. Novel plant microRNAs from broccoletti sprouts do not show cross-kingdom regulation of pancreatic cancer. Last author DOI 10.18632/oncotarget.27527↗
  29. Novel Broccoli Sulforaphane-Based Analogues Inhibit the Progression of Pancreatic Cancer without Side Effects. Last author DOI 10.3390/biom10050769↗
  30. MicroRNA-365a-3p inhibits c-Rel-mediated NF-κB signaling and the progression of pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.03.025↗
  31. Sulforaphane Induces miR135b-5p and Its Target Gene, RASAL2, thereby Inhibiting the Progression of Pancreatic Cancer. Last author DOI 10.1016/j.omto.2019.03.011↗
  32. Interleukin 21 Receptor/Ligand Interaction Is Linked to Disease Progression in Pancreatic Cancer. Co-author DOI 10.3390/cells8091104↗
  33. Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-β-driven progression of pancreatic cancer. Last author DOI 10.3892/ijo.2018.4616↗
  34. Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer. Last author DOI 10.1016/j.canlet.2018.04.001↗
  35. microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. Last author DOI 10.1016/j.canlet.2016.11.035↗
  36. Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGFβ and JNK/AP-1. Last author DOI 10.1038/cddis.2017.455↗
  37. Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer. Last author DOI 10.1186/s12943-017-0589-8↗
  38. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Last author DOI 10.1016/j.canlet.2016.01.038↗
  39. Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy. Last author DOI 10.1038/cddis.2016.157↗
  40. Up-regulation of microRNA let-7c by quercetin inhibits pancreatic cancer progression by activation of Numbl. Last author DOI 10.18632/oncotarget.11122↗
  41. Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells. Last author DOI 10.18632/oncotarget.7031↗
  42. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Last author DOI 10.18632/oncotarget.3171↗
  43. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Last author DOI 10.1002/ijc.28583↗
  44. Pilot study evaluating broccoli sprouts in advanced pancreatic cancer (POUDER trial) - study protocol for a randomized controlled trial. Co-author DOI 10.1186/1745-6215-15-204↗
  45. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication. Last author DOI 10.18632/oncotarget.1764↗
  46. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Last author DOI 10.18632/oncotarget.2120↗
  47. Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition. Last author DOI 10.3892/ijo.2014.2539↗
  48. Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer. Last author DOI 10.3892/or.2014.3196↗
  49. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Last author DOI 10.1038/cddis.2013.158↗
  50. Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer. Co-author DOI 10.4161/onci.19532↗

Trials 1

  1. Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] Principal investigator NCT01879878↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Schaefer · 10 shared papers, 2014–2025 · strength 1.62
  2. Clifford C. Nwaeburu · 15 shared papers, 2013–2025 · strength 1.56
  3. Li Liu · 12 shared papers, 2014–2024 · strength 1.55
  4. Nathalie Bauer · 13 shared papers, 2014–2024 · strength 1.20
  5. Bin Yan · 7 shared papers, 2021–2025 · strength 1.20
  6. Chao Fang · 5 shared papers, 2025–2026 · strength 1.03
  7. Christoph W. Michalski · 5 shared papers, 2025–2026 · strength 1.03
  8. Alia Abukiwan · 7 shared papers, 2016–2025 · strength 1.02
  9. Kangtao Wang · 4 shared papers, 2021–2025 · strength 1.02
  10. Xuefeng An · 6 shared papers, 2021–2023 · strength 0.88
  11. Libo Yin · 8 shared papers, 2018–2021 · strength 0.80
  12. Oliver Strobel · 7 shared papers, 2015–2024 · strength 0.76
  13. Yiqiao Luo · 6 shared papers, 2019–2022 · strength 0.74
  14. Tobias Pfeifer · 4 shared papers, 2021–2024 · strength 0.68
  15. Liping Bai · 4 shared papers, 2021–2024 · strength 0.68
  16. Thilo Hackert · 7 shared papers, 2014–2024 · strength 0.62
  17. Lian Zhao · 3 shared papers, 2022–2025 · strength 0.59
  18. Xi Xiao · 6 shared papers, 2016–2022 · strength 0.59
  19. Christoph Kahlert · 3 shared papers, 2025–2026 · strength 0.59
  20. Franco Fortunato · 4 shared papers, 2015–2026 · strength 0.58
  21. Yifeng Sun · 3 shared papers, 2025 · strength 0.57
  22. Li Liu · 5 shared papers, 2019–2023 · strength 0.55
  23. Christina Georgikou · 5 shared papers, 2019–2020 · strength 0.51
  24. Nathalia A. Giese · 5 shared papers, 2013–2024 · strength 0.50
  25. Pei Fan · 7 shared papers, 2014–2024 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.